Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer

NCT04364048 is registered in ClinicalTrials.gov with Rachel Sanborn as lead sponsor.

NCT NCT04364048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04364048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Lead sponsor
Rachel Sanborn
Phase
Phase 2
Overall status
Terminated
Start date
June 18, 2020
Completion date
February 5, 2024
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell carcinoma